Charles Schwab Investment Management Inc. Has $8.67 Million Stock Position in Arcus Biosciences, Inc. (NYSE:RCUS)

Charles Schwab Investment Management Inc. grew its position in shares of Arcus Biosciences, Inc. (NYSE:RCUS - Free Report) by 11.7% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 566,979 shares of the company's stock after acquiring an additional 59,536 shares during the quarter. Charles Schwab Investment Management Inc. owned 0.62% of Arcus Biosciences worth $8,669,000 at the end of the most recent reporting period.

Several other large investors have also added to or reduced their stakes in RCUS. Innealta Capital LLC acquired a new position in Arcus Biosciences during the second quarter valued at approximately $66,000. Point72 DIFC Ltd acquired a new stake in shares of Arcus Biosciences in the 2nd quarter valued at approximately $83,000. Quest Partners LLC boosted its holdings in shares of Arcus Biosciences by 40,904.3% in the 3rd quarter. Quest Partners LLC now owns 9,431 shares of the company's stock valued at $144,000 after buying an additional 9,408 shares during the last quarter. Diversified Trust Co lifted its stake in Arcus Biosciences by 12.1% in the second quarter. Diversified Trust Co now owns 13,545 shares of the company's stock valued at $206,000 after acquiring an additional 1,467 shares during the last quarter. Finally, Intech Investment Management LLC acquired a new stake in Arcus Biosciences in the third quarter valued at $244,000. Institutional investors and hedge funds own 92.89% of the company's stock.

Analyst Upgrades and Downgrades

RCUS has been the subject of a number of recent analyst reports. Cantor Fitzgerald reiterated an "overweight" rating on shares of Arcus Biosciences in a research note on Thursday, October 3rd. HC Wainwright reaffirmed a "neutral" rating and issued a $20.00 price objective on shares of Arcus Biosciences in a research report on Wednesday, November 6th. Wedbush reissued an "outperform" rating and set a $36.00 target price on shares of Arcus Biosciences in a report on Thursday, November 7th. Barclays raised their price target on Arcus Biosciences from $25.00 to $29.00 and gave the company an "overweight" rating in a report on Friday, October 25th. Finally, Wells Fargo & Company initiated coverage on shares of Arcus Biosciences in a research report on Tuesday, October 8th. They issued an "overweight" rating and a $29.00 price objective on the stock. One analyst has rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Buy" and an average price target of $34.00.

Arcus Biosciences Stock Performance

Shares of RCUS traded up $0.54 during midday trading on Wednesday, reaching $17.96. 541,813 shares of the stock were exchanged, compared to its average volume of 728,701. The company has a quick ratio of 5.24, a current ratio of 5.24 and a debt-to-equity ratio of 0.08. Arcus Biosciences, Inc. has a twelve month low of $13.52 and a twelve month high of $20.31. The stock's 50 day simple moving average is $16.46 and its 200 day simple moving average is $16.02. The company has a market cap of $1.64 billion, a P/E ratio of -5.53 and a beta of 0.88.

Arcus Biosciences (NYSE:RCUS - Get Free Report) last announced its quarterly earnings data on Wednesday, November 6th. The company reported ($1.00) earnings per share for the quarter, beating the consensus estimate of ($1.06) by $0.06. The firm had revenue of $48.00 million during the quarter, compared to analysts' expectations of $38.95 million. Arcus Biosciences had a negative return on equity of 45.59% and a negative net margin of 102.66%. The company's quarterly revenue was up 50.0% compared to the same quarter last year. During the same period in the previous year, the firm earned ($0.94) EPS. On average, sell-side analysts expect that Arcus Biosciences, Inc. will post -3.2 earnings per share for the current year.

About Arcus Biosciences

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.